Nabriva Therapeutics AG Shares Outstanding 2015-2021 | NBRV

Nabriva Therapeutics AG shares outstanding from 2015 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Nabriva Therapeutics AG Annual Shares Outstanding
(Millions of Shares)
2020 128
2019 74
2018 51
2017 30
2016 21
2015 1
2014 0
Nabriva Therapeutics AG Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 406
2021-03-31 264
2020-12-31 128
2020-09-30 145
2020-06-30 113
2020-03-31 95
2019-12-31 74
2019-09-30 75
2019-06-30 73
2019-03-31 69
2018-12-31 51
2018-09-30 58
2018-06-30 41
2018-03-31 37
2017-12-31 30
2017-09-30 28
2017-06-30 27
2017-03-31 27
2016-12-31 21
2016-09-30 21
2016-06-30 21
2016-03-31 2
2015-12-31 1
2015-09-30
2015-06-30 1
2015-03-31 0
2014-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.560B $0.005B
Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics' medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics' lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP).
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.460B 8.55
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $8.952B 0.00
Emergent Biosolutions (EBS) United States $2.717B 6.55
Arcus Biosciences (RCUS) United States $2.502B 0.00
Myovant Sciences (MYOV) United Kingdom $1.906B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.820B 0.00
Zymeworks (ZYME) Canada $1.088B 0.00
Ambrx Biopharma (AMAM) United States $0.513B 0.00
SQZ Biotechnologies (SQZ) United States $0.343B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.57